EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness

Rebecca A Hermans iD, Sebastiaan D T Sassen, Sanne Maartje Kloosterboer iD, Catrien G Reichart, Mirjam E J Kouijzer, Matthias M J de Kroon, Dennis Bastiaansen, Daphne van Altena, Ron H N van Schaik, Kazem Nasserinejad iD, Manon H J Hillegers, Birgit C P Koch iD und 2 weitere

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15800 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Rebecca A Hermans und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Autism Spectrum Disorder, Antipsychotic Agents, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Aripiprazole is one of the most commonly prescribed antipsychotic drugs to children and adolescents worldwide, but it is associated with serious side‐effects, including weight gain. This study assessed the population pharmacokinetics of aripiprazole and its active metabolite and investigated the relationship between pharmacokinetic parameters and body mass index (BMI) in children and adolescents with autism spectrum disorder (ASD) and behavioural problems. Secondary outcomes were metabolic, endocrine, extrapyramidal and cardiac side‐effects and drug effectiveness.

Methods

Twenty‐four children and adolescents (15 males, 9 females) aged 6–18 years were included in a 24‐week prospective observational trial. Drug plasma concentrations, side‐effects and drug effectiveness were measured at several time points during follow‐up. Relevant pharmacokinetic covariates, including CYP2D6, CYP3A4, CYP3A5 and P‐glycoprotein (ABCB1) genotypes, were determined. Nonlinear mixed‐effects modelling (NONMEM®) was used for a population pharmacokinetic analysis with 92 aripiprazole and 91 dehydro‐aripiprazole concentrations. Subsequently, model‐based trough concentrations, maximum concentrations and 24‐h area under the curves (AUCs) were analysed to predict outcomes using generalized and linear mixed‐effects models.

Results

For both aripiprazole and dehydro‐aripiprazole, one‐compartment models best described the measured concentrations, with albumin and BMI as significant covariates. Of all the pharmacokinetic parameters, higher sum (aripiprazole plus dehydro‐aripiprazole) trough concentrations best predicted higher BMI z ‐scores ( P < .001) and higher Hb1Ac levels ( P = .03) during follow‐up. No significant association was found between sum concentrations and effectiveness.

Conclusions

Our results indicate a threshold with regard to safety, which suggests that therapeutic drug monitoring of aripiprazole could potentially increase safety in children and adolescents with ASD and behavioural problems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autism Spectrum DisorderAntipsychotic AgentsDrug-Related Side Effects and Adverse ReactionsMaleFemaleAdolescentChildHumansAripiprazoleWeight GainBody Mass Index

Stichwörter der Autor:innen

antipsychoticspaediatric patientspharmacometricsprecision dosingside-effects

Substanzen

AripiprazoleAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, The Netherlands.
  • Department of Child and Adolescent Psychiatry/Psychology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Rotterdam Clinical Pharmacometrics Group, Erasmus Medical Center, Rotterdam, The Netherlands.
  • LUMC-Curium Child and Adolescent Psychiatry, Leiden University Medical Center, Oegstgeest, The Netherlands.
  • GGz Breburg, Centre of Youth, Breda, the Netherlands.
  • de Kroon Child Psychiatry, Breda, the Netherlands.

ORCID-Profile: Rebecca A Hermans, Sanne Maartje Kloosterboer, Kazem Nasserinejad, Birgit C P Koch

Förderung

  • ZonMw

Zitieren

APA

Hermans, R. A., Sassen, S. D. T., Kloosterboer, S. M., Reichart, C. G., Kouijzer, M. E. J., de Kroon, M. M. J., Bastiaansen, D., van Altena, D., van Schaik, R. H. N., Nasserinejad, K., Hillegers, M. H. J., Koch, B. C. P., Dierckx, B., & de Winter, B. C. M. (2023). Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15800

Vancouver

Hermans RA, Sassen SDT, Kloosterboer SM, Reichart CG, Kouijzer MEJ, de Kroon MMJ, et al. Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15800

BibTeX
@article{Hermans2023,
  author = {Hermans, Rebecca A and Sassen, Sebastiaan D T and Kloosterboer, Sanne Maartje and Reichart, Catrien G and Kouijzer, Mirjam E J and de Kroon, Matthias M J and Bastiaansen, Dennis and van Altena, Daphne and van Schaik, Ron H N and Nasserinejad, Kazem and Hillegers, Manon H J and Koch, Birgit C P and Dierckx, Bram and de Winter, Brenda C M},
  title = {Towards precision dosing of aripiprazole in children and adolescents with autism spectrum disorder: Linking blood levels to weight gain and effectiveness},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15800}
}
Kostenlos starten →